ReviewClinical journal of the American Society of Nephrology : CJASN2013
Cardiorenal syndrome: new developments in the understanding and pharmacologic management.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- 10-Year Trends in Heart Failure Among Patients With Dialysis and Nondialysis CKD.Kidney international reports · 2026Article
- Diuretic Use in Heart Failure.Reviews in cardiovascular medicine · 2025Review
- Effect of blood pressure index on clinical outcomes in patients with heart failure and chronic kidney disease.ESC heart failure · 2023Article
- Perirenal Fat and Kidney Function Deterioration in Patients With Acute Decompensated Heart Failure.International journal of heart failure · 2023Article
- Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease.Kidney research and clinical practice · 2021Article
- miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome.Frontiers in pharmacology · 2020Review
- Increased susceptibility to structural acute kidney injury in a mouse model of presymptomatic cardiomyopathy.American journal of physiology. Renal physiology · 2017Article
- Echocardiographic Measures and Estimated GFR Decline Among African Americans: The Jackson Heart Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Article
- Peripheral Edema, Central Venous Pressure, and Risk of AKI in Critical Illness.Clinical journal of the American Society of Nephrology : CJASN · 2016Article
- The cytohesin guanosine exchange factors (GEFs) are required to promote HGF-mediated renal recovery after acute kidney injury (AKI) in mice.Physiological reports · 2015Article
- NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.Clinical journal of the American Society of Nephrology : CJASN · 2015Article
- Cardiorenal syndrome: introduction.Clinical journal of the American Society of Nephrology : CJASN · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiorenal syndromes (CRSs) with bidirectional heart-kidney signaling are increasingly being recognized for their association with increased morbidity and mortality. In acute CRS, recognition of the importance of worsening kidney function complicating management of acute decompensated heart failure has led to the examination of this specific outcome in the context of acute heart failure clinical trials. In particular, the role of fluid overload and venous congestion has focused interest in the most effective use of diuretic therapy to relieve symptoms of heart failure while at the same time preserving kidney function. Additionally, many novel vasoactive therapies have been studied in recent years with the hopes of augmenting cardiac function, improving symptoms and patient outcomes, while maintaining or improving kidney function. Similarly, recent advances in our understanding of the pathophysiology of chronic CRS have led to reanalysis of kidney outcomes in pivotal trials in chronic congestive heart failure, and newer trials are including changes in kidney function as well as kidney injury biomarkers as prospectively monitored and adjudicated outcomes. This paper provides an overview of some new developments in the pharmacologic management of acute and chronic CRS, examines several reports that illustrate a key management principle for each subtype, and discusses opportunities for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.